Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Arch Gynecol Obstet ; 309(6): 2891-2896, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38578543

RESUMEN

PURPOSE: Nifedipine is a calcium channel blocker with smooth muscle relaxing properties. This study set out to investigate the efficacy of nifedipine administered orally before embryo transfer (ET) on the improvement of the intracytoplasmic sperm injection (ICSI) outcome. This randomized, double-blind, comparator-controlled, was carried out between 2019 and 2020 in the infertility center of Babol, Iran. 200 women candidates for ICSI and recipients of frozen-thawed ET aged 18-40 years were randomly assigned in the ratio 1:1 to an intervention group that received nifedipine 20 mg tablets orally 30 min before ET (n = 100) or to a group of placebo (n = 100). A randomization center in Babol University of Medical Science used computer-generated numbers to allocate treatments. The allocation treatment was blind to the participants, the sonographer of endometer monitoring, the staff of the ICSI laboratory, and the outcome assessor. The primary analysis was based on the intention-to-treat principle done on 200 participants, (n = 100), comparing chemical pregnancy rates in the two comparing groups at 14 days' follow-up after ET. Implantation rate and clinical pregnancy were considered secondary outcomes. RESULT: 200 participants were analyzed. There is no significant difference in the number of oocytes and the quality of embryos in the nifedipine and placebo groups. Despite a numerical increase in the rate of chemical pregnancy, there were no statistical differences in the study group versus the comparison group (24% vs 14%, P = 0.1, rate ratio 0.88, 95% CI 0.77 to 1.01), respectively. Also, no significant increase in clinical pregnancy was found compared with the placebo (17% vs 8%, P = 0.26, rate ratio 0.90, 0.81 to 1.00). CONCLUSION: Nifedipine administered orally 30 min before embryo transfer did not improve the chemical pregnancy rate, and clinical pregnancy rate in infertile women undergoing ICSI. This trial has been registered on the Iranian Clinical Trials Registration Site (IRCT) with the number IRCT20180417039338N3.


Asunto(s)
Bloqueadores de los Canales de Calcio , Transferencia de Embrión , Nifedipino , Índice de Embarazo , Inyecciones de Esperma Intracitoplasmáticas , Humanos , Nifedipino/administración & dosificación , Femenino , Método Doble Ciego , Embarazo , Adulto , Transferencia de Embrión/métodos , Bloqueadores de los Canales de Calcio/administración & dosificación , Irán , Adulto Joven , Implantación del Embrión/efectos de los fármacos , Administración Oral
2.
J Hum Reprod Sci ; 16(4): 352-357, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38322638

RESUMEN

Background: Several genetic mutations in female thrombotic defects have recently been shown to affect recurrent pregnancy loss (RPL); however, it is unclear which common parental mutations are involved in thrombosis-associated repeated pregnancy loss RPL. Aims: In this study, the prevalence of some combined parental thrombophilia gene mutation defects was studied in couples with RPL. Settings and Design: The observational study was done in babol infertility research center (Iran) in 2022. Materials and Methods: Sixty-two infertile women with a history of RPL and their male partners (124 individuals) participated in this study. The frequencies of common defects associated with methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, factor V Leiden, protein C, protein S and homocysteine were analysed in these couples. Statistical analysis used: The data were statistically analysed using the Mann-Whitney test. Results: Sixty-two couples (124 individuals) were analysed. 56.2% of couples with a history of RPL had MTHFR C677T and 23.1% had MTHFR A1298C. Forty percent of couples showed homocysteine deficiency and 12.5% protein C deficiency. Other genes tested were only observed in the mother or father but not both. Conclusions: Results obtained with RPL couples demonstrate the importance of further investigating combined parental thrombophilia gene mutation defects (not only maternal).

3.
Risk Anal ; 42(8): 1852-1871, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-33506515

RESUMEN

An incident in which a rail defect of size over a threshold value is noticed and the track is taken out of service is known as a service failure. This article aims at building accurate prediction models with binary outcome for risk of service failures on heavy haul rail segments. An analysis of the factors that influence the risk of a service failure is conducted and quantitative models are developed to predict locations where service failures are most likely to occur until the next inspection. To this end, data are collected from a Class I U.S. Railroads for six years from 2011 to 2016. Four prediction models (i.e., logistic regression, decision tree, multilayer perceptron, and gradient boosting classifier) are implemented and their results are compared. To account for the imbalanced classes between the normal operation and service failure, two treatments have been used including undersampling and oversampling. To improve the model performance, the parameters of each method are tuned using random search hyperparameter optimization. Later, bootstrap aggregation (or bagging) is incorporated into each method. The findings of the study show that the prediction performance is the highest when using bagging and oversampling as treatments with gradient boosting method. It was also identified that gross tonnage, presence of geometry defects, ambient temperature, segment length, and rail defect presence are the most important factors for predicting the risk of service failures. The results of this study are useful for railroads to develop effective strategies for rail inspections, preventive maintenance, and capital planning.

4.
Int J Reprod Biomed ; 14(1): 39-46, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27141547

RESUMEN

BACKGROUND: The use of assisted reproductive technology (ART) is increasing in the world. The rate, efficacy and safety of ART are very different among countries. There is an increase in the use of intra cytoplasmic sperm injection (ICSI), single fresh embryo transfer (ET) and frozen-thawed embryo transfer (FET). OBJECTIVE: The objective of this study was to compare pregnancy rate in fresh ET and FET. MATERIALS AND METHODS: In this retrospective cross-sectional study 1014 ICSI-ET cycles (426 fresh ET and 588 FET) from 753 women undergoing ICSI treatment referred to Fatemezahra Infertility and Reproductive Health Research Center in Babol, Iran from 2008 to 2013 were reviewed. RESULTS: There were no significant differences between biochemical pregnancy rate (23% versus 18.8%, OR 1.301; 95% CI .95-1.774), gestational sac (95.6% versus 100% in FET, OR 0.60; 95% CI 0.54-0.67), and fetal heart activity (87.2% versus 93.6% OR .46; 95% CI .16-1.32) in fresh ET and FET cycles, respectively. P< 0.05 was considered statistically significant for all measures. CONCLUSION: Although, the result showed no significantly difference between the fresh ET and the FET cycles, however the embryos are able to be stored for subsequent ART. Therefore, we recommend FET cycles as an option alongside the fresh ET.

5.
J Reprod Infertil ; 15(4): 205-13, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25473629

RESUMEN

BACKGROUND: This study was designed to investigate the effect of metformin and flutamide alone or in combination with anthropometric indices and laboratory tests of obese/overweight PCOS women under hypocaloric diet. METHODS: This single blind clinical trial was performed on 120 PCOS women. At the beginning, hypocaloric diet was recommended for the patients. After one month while they were on the diet, the patients were randomly divided in 4 groups; metformin (500 mg, 3/day), flutamide (250 mg, 2/day), combined, metformin (500 mg, 3/day) with flutamide (250 mg, 2/day) and finally placebo group. The patients were treated for 6 months. Anthropometric indices and laboratory tests (fasting and glucose-stimulated insulin levels, lipid profile and androgens) were measured. A one-way ANOVA (Post Hoc) and paired t-test were performed to analyze data. A p ≤ 0.05 was considered statistically significant. RESULTS: After treatment, reduction in weight, BMI, hip circumference was significantly greater in the metformin group in comparison to other groups (p<0.05). In addition, the fasting insulin was significantly greater in metformin group and flutamide group in comparison to metformin+flutamide and placebo groups after treatment (p<0.05). Within groups, insulin level showed significant changes (before and after treatment) in metformin+flutamide group and LDL reduction was significant in flutamide group before and after treatment. Post hoc tukey and two-tailed with p≤0.05 were used to define statistical significance. CONCLUSION: Using combination of metformin and flutamide improves anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...